本帖最后由 老马 于 2012-1-13 21:20 编辑 5 Q. ]' R: H, m% p3 z2 X* ^9 O
3 ^+ z" A: h3 {+ M: k0 C* D
爱必妥和阿瓦斯丁的比较
1 d# u4 t3 y0 ~
2 c3 M3 V3 v. i
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" M* C/ t7 J) ~5 c
) c" R' `" s% W
% L4 s$ A4 n6 _http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 [ l2 |& {. D$ t( c% T0 O$ A
==================================================9 T0 Y* Q! _9 s5 s
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 Y$ [" A& X& m% EPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 X% Q- J/ f: M3 n0 m2 k
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' x, F' E% Q1 o n! K- k/ O! U
|
显身卡
9 j$ B8 e& C" s9 o
